CYNAERA U.S. Chronic Condition Prevalence Database™

The Largest U.S. Chronic Condition Prevalence Database

The CYNAERA U.S. Chronic Condition Prevalence Database™ brings together prevalence estimates for over 1,000 chronic conditions across 20 medical specialty categories. Developed by Cynthia Adinig, the resource combines published epidemiological evidence with CYNAERA's proprietary population modeling frameworks to examine chronic disease burden, diagnostic undercounting, and gaps in U.S. prevalence reporting.

The database includes rare diseases, infection-associated chronic conditions, autoimmune disorders, neurological diseases, cardiovascular conditions, environmental illnesses, and other complex health conditions. Where reliable U.S. estimates are unavailable, CYNAERA evaluates applicable international evidence, population characteristics, and diagnostic limitations to develop modeled national estimates.

1000+ modeled condition records | 20 research categories | U.S. demographic prevalence

Download Database PDF

Methodology

Explore Chronic Condition Prevalence Across 20 Medical Specialties

Browse the database by medical specialty to access condition-specific research, prevalence estimates, and available publications. Categories organize related conditions for easier exploration, including diseases that overlap multiple specialties. Individual category totals represent combined condition estimates and should not be interpreted as counts of unique patients.

Select a letter below to jump to its section.

A

B

C

D

E

F

G

H

I

J

Jervell and Lange-Nielsen syndrome | 547–2,051
Juvenile absence epilepsy | 34,178

Juvenile idiopathic arthritis | 600,000
Juvenile myelomonocytic leukemia | 342

Juvenile myoclonic epilepsy | 34,178–68,357
Juvenile polyposis syndrome | 3,418

K

Klippel-Trenaunay syndrome | 3,418
Knee osteoarthritis | 1.76 million
Koolen-de Vries syndrome | 21,362
Krabbe disease | 3,418

L

M

N

Non-Hodgkin lymphoma | 879,290
Nontoxic goiter | 1.35 million
Normal pressure hydrocephalus | 800,000

O

P

Q

Qazi-Markouizos syndrome | 3
QRICH1-related syndrome | Fewer than 342

Quadricuspid aortic valve | 44,432–146,967
Quadriplegia | 184,246

Quadruple X syndrome | 40
Quebec platelet disorder | 522

R

S

T

U

V

W

X

Y

Yao syndrome | 3,418–34,178
Y-chromosome microdeletion syndrome | 67,126

Yellow nail syndrome | 171
Yemenite deaf-blind hypopigmentation syndrome | 1

Yorifuji-Okuno syndrome | 1
Yunis-Varon syndrome | 2

Z

Zebra body myopathy | 3
Zellweger spectrum disorder | 6,836

Zimmermann-Laband syndrome | 50

Zollinger-Ellison syndrome | 3,418–30,761

Research developed by Cynthia Adinig, CYNAERA Institute.

Isometric Library Research Scene_edited.

Understanding Combined Condition Prevalence

The database incorporates published population estimates alongside CYNAERA-modeled prevalence calculations. Depending on the condition and available evidence, modeling may address diagnostic undercounting, incomplete surveillance, international prevalence differences, demographic characteristics, or disease-specific risk factors. Modeled estimates are research projections rather than directly observed patient counts. Methods, assumptions, and uncertainty vary by condition, and estimates may change as new evidence becomes available.

CYNAERA Research Capabilities

Research Methodology: Beyond Conventional Prevalence Reporting

Traditional disease prevalence estimates depend heavily on diagnosed patients, established surveillance programs, published epidemiological studies, and conditions that healthcare systems consistently recognize. These sources provide essential evidence, but they do not always capture the full population living with chronic illness. Patients may remain undiagnosed for years, receive multiple incomplete diagnoses, or experience conditions that are not consistently tracked through national surveillance. Other diseases have substantial international research but limited U.S. population estimates. For ultra-rare disorders, the available evidence may consist of only a handful of documented cases worldwide.

The CYNAERA U.S. Chronic Condition Prevalence Database™ addresses these challenges through a multi-framework research methodology designed to distinguish documented prevalence from potentially unrecognized or incompletely measured disease burden. Rather than treating missing national statistics as evidence that a condition is absent, CYNAERA evaluates available evidence and applies relevant population modeling methods to develop additional estimates.

An Integrated Population Modeling Architecture

CYNAERA's methodology combines epidemiological research with independently developed analytical frameworks. Each framework addresses a different source of uncertainty or undermeasurement, allowing the database to use approaches appropriate to the condition and available evidence.

U.S. Chronic Condition Undercount Correction (US-CCUC™)

US-CCUC™ examines differences between conventionally reported disease prevalence and the potential number of people living with a condition in the United States. Its applications consider relevant gaps in surveillance, diagnostic recognition, and population representation. The framework supports the development of adjusted national estimates where published statistics may not fully reflect the affected population. Existing modeled estimates are preserved and evaluated within their original methodological context rather than indiscriminately replaced by newer international figures.

Diagnostic Multiplier™

The Diagnostic Multiplier™ addresses potential differences between diagnosed populations and the broader population experiencing a condition. It considers applicable evidence concerning delayed diagnosis, missed diagnoses, inconsistent recognition, and other barriers affecting diagnostic capture.

This distinction is particularly important for complex chronic illnesses, rare disorders, and conditions whose clinical presentation overlaps with multiple specialties. Diagnostic adjustment is applied selectively rather than assuming every disease has the same degree of underrecognition.

Global to National Prevalence Translation Model (GNPTM™)

GNPTM™ addresses a different problem: conditions for which meaningful international prevalence evidence exists but reliable U.S. population estimates are limited or unavailable. The model evaluates international epidemiological findings and their applicability to the American population. Its analytical considerations include source reliability, diagnostic recognition, demographic eligibility, geographic variation, and disease-specific population characteristics.

International prevalence rates are not automatically applied to the entire U.S. population. Where appropriate, GNPTM™ accounts for differences in source populations, ancestry, age, sex, disease distribution, and other factors that affect comparability. This provides a structured alternative to either excluding a condition because domestic surveillance is incomplete or assuming that a foreign country's observed prevalence applies universally.

US-CCUC™

Diagnostic Multiplier™

Terrain-Based International Comparisons

An important feature of CYNAERA's research architecture is its evaluation of population terrain: the combination of relevant environmental, structural, diagnostic, and biological circumstances that can influence chronic disease burden. Through applicable components of CCUC-Global™ and related frameworks, CYNAERA examines differences between countries that may affect disease occurrence, recognition, persistence, and the number of people living with a condition.

Countries with comparable terrain classifications may provide useful starting points for prevalence translation. Where a target population has a higher relevant risk burden, an upward adjustment may be appropriate. Where risk is lower, a downward adjustment may be appropriate. These comparisons are condition-specific. Environmental terrain, diagnostic visibility, and inherited genetic frequency are not treated as interchangeable. An adjustment that is relevant to an infection-associated condition may not be appropriate for a congenital disorder driven by a founder mutation. This approach allows international evidence to be interpreted through the characteristics of the affected population rather than geographic location alone.

Estimating Conditions With Fewer Than 100 Documented Cases Worldwide

The GNPTM™ Tier Matched Ultra-Rare Estimation Pathway extends the methodology to an especially difficult research category: conditions with fewer than 100 documented patients worldwide. Conventional statistical reporting frequently provides little useful national prevalence information for these disorders. Published evidence may be limited to individual families, clinical case reports, or small groups of patients identified in different countries. CYNAERA's ultra-rare pathway evaluates available case evidence alongside relevant source populations, international terrain comparisons, diagnostic ascertainment, survival, and genetic or demographic distribution.

The model avoids simply dividing a small worldwide case total among countries. Instead, it develops an estimated national burden using applicable population comparisons and explicitly identified assumptions. Because extremely small populations can produce fractional expected case counts, the methodology preserves those values during calculation before generating whole-number public estimates. A rounded count represents a modeled population expectation rather than confirmation that a specific number of individuals has been identified. Ultra-rare projections are particularly sensitive to assumptions and are interpreted as exploratory estimates where population evidence remains limited.

Incorporating Chronicity and Disease Persistence

For conditions affected by initiating infections, environmental exposures, physiological vulnerabilities, or recovery barriers, CYNAERA may incorporate relevant concepts from its Primary Chronic Trigger (PCT™) framework. These considerations help distinguish the occurrence of a triggering event from the population that subsequently develops persistent disease.

The methodology also recognizes the difference between incidence, which measures new cases over a defined period, and prevalence, which measures people living with a condition at a given time. Where incidence evidence is used to estimate prevalence, disease duration, survival, and other appropriate factors must be considered. Chronicity-related adjustments are not applied automatically to every condition. Their use depends on whether the condition's biological and epidemiological evidence supports the connection.

Primary Chronic Trigger (PCT™)

Evidence Integration and Quality Controls

The database draws on applicable government health statistics, population studies, disease registries, published research, international epidemiological findings, and rare-disease resources. Evidence is evaluated according to its relevance to the condition, the population represented, the type of measurement reported, and the limitations of the underlying source.

The methodology distinguishes among:

Published prevalence estimates: Population figures reported by identifiable epidemiological or surveillance sources.
Adjusted prevalence estimates: Figures developed by applying relevant corrections to an existing evidence base.
Internationally translated estimates: National projections derived from applicable prevalence evidence in other countries.
Ultra-rare modeled estimates: Exploratory national estimates developed from limited case evidence and population-specific assumptions.

Where appropriate, CYNAERA examines demographic eligibility, overlapping disease classifications, duplicated condition names, study uncertainty, and differences in diagnostic criteria. Modeled figures are estimates of population burden, not verified counts of identified patients. The degree of uncertainty varies across conditions and may be substantial when evidence is sparse.

Implications for Population-Level Research

Differences in diagnostic recognition, surveillance coverage, and epidemiological reporting can produce substantial variation between documented prevalence and estimated disease burden. These limitations affect the interpretation of population statistics, particularly for conditions with overlapping clinical presentations, incomplete diagnostic pathways, or limited national surveillance.

CYNAERA's integrated modeling architecture provides additional methods for assessing those discrepancies across disease categories and geographic populations. By combining diagnostic undercount correction, international prevalence translation, terrain-based comparisons, and ultra-rare population estimation, the database supports a more comprehensive examination of chronic illness prevalence than reliance on any single reporting system. The resulting estimates can inform epidemiological research, clinical trial population assessments, health system planning, and the evaluation of research priorities. Their interpretation depends on the quality of source evidence, the applicability of model assumptions, and the uncertainty associated with each condition.

Achievements

Research Access, Citation, and Licensing

The database supports research discovery, epidemiological analysis, public health planning, clinical research, and population-level forecasting. CYNAERA also offers institutional research access, customized prevalence modeling, specialty-specific datasets, and commercial licensing opportunities. Public access to prevalence information does not convey ownership of CYNAERA's proprietary algorithms, modeling systems, or independently licensed research assets.

Contact

Case Studies